Article Per Year (5 Year)
p-Index From 2021 - 2026
0
P-Index
This Author published in this journals
All Journal Paediatrica Indonesiana
Himmet Haluk Akar
İstanbul Health Sciences University, Kanuni Sultan Süleyman Training and Research Hospital Department of Pediatric Immunology and Allergy, İstanbul/Turkey
Health Professions Medicine & Pharmacology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search
Journal : Paediatrica Indonesiana

 1 
Increased lipoxin B4 levels in children with atopic dermatitis Himmet Haluk Akar; Mikdat Yildiz
Paediatrica Indonesiana Vol 59 No 5 (2019): September 2019
Publisher : Indonesian Pediatric Society

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (309.064 KB) | DOI: 10.14238/pi59.5.2019.271-5

Abstract

Background Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in the pediatric population. The pathophysiology of AD is complex and not clearly understood. The role of lipoxin B4 (LXB4), an anti-inflammatory mediator, has not been sufficiently investigated in children with AD to our knowledge. Objective To compare the levels of serum LXB4 between children with AD and healthy controls. Methods Three groups of children were enrolled in this study: a SPT-Pos group (skin prick test positive 21 subjects with AD), a SPT-Neg group (skin prick test negative 22 subjects with AD), and a control group (23 healthy subjects). Subjects’ serum LXB4 levels of were measured with an ELISA technique. Also, eosinophil counts and total immunoglobulin E (IgE) levels were compared among all groups. Results We observed significantly higher LXB4 levels in AD patients than in controls. Also, LXB4 levels were significantly higher in the SPT-Pos group than in the SPT-Neg group and control group. However, no significant difference was observed between the SPT-Neg and control groups. Conclusion The LXB4 may have an anti-inflammatory mediator role in the pathogenesis of AD in children. The LXB4-associated pathways may be considered in the development of novel therapeutic approaches for the treatment of patients with AD.
Co-Authors Mikdat Yildiz